News - BioSpace
This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and AbbVie, following the predictable pattern of successes and failures that characterizes this space.
BioSpace: Biotech, Pharmaceutical and Clinical Research News
Dec 11, 2010 · GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment model; Eli Lilly and Novo Nordisk pump new funds into manufacturing; and AbbVie makes a Cerevel comeback while uniQure clears a path toward …
Stubborn Layoff Trend Continues Across Biopharma in 2024
Dec 23, 2024 · 2023 was a tough year for the biopharma industry, with several companies downsizing and restructuring their workforces to stay afloat. And unfortunately, 2024 was more of the same, with some companies including Bayer, Bristol Myers Squibb and Johnson & Johnson are cutting hundreds or even thousands of employees.. BioSpace will continue to be your …
Join Our Team - BioSpace
BioSpace is the digital hub for life sciences news and jobs. Our mission is to provide essential insights, tools, and opportunities to connect the innovative organizations and talented professionals who advance health and quality of life across the globe.
About Us - BioSpace
BioSpace is the digital hub for life science news and jobs.We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.
AstraZeneca’s Truqap Redeems Itself with Phase III ... - BioSpace
Nov 26, 2024 · AstraZeneca on Monday released high-level data from the Phase III CAPItello-281 trial, demonstrating that a combo regimen based on its AKT inhibitor Truqap (apivasertib) significantly boosts radiographic progression-free survival in patients with one type of prostate cancer.. Without providing specific data from the study, AstraZeneca revealed that Truqap plus …
CAR T for Lupus Takes Center Stage at ACR 2024 - BioSpace
Nov 19, 2024 · While CAR T cell therapies are pricey—BMS’s Breyanzi is over $480,000 for one suspension—the potential to have a one-time infusion for a long-lasting, drug-free remission would be highly appealing to lupus patients who otherwise face a lifetime of ongoing medications, Badyal said. Companies working in this space will need to consider how they can make these …
ESSENCE Phase 3 trial results demonstrating statistically
The trial achieved both its primary endpoints, with semaglutide 2.4 mg demonstrating statistically significant and superior improvements in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH compared to placebo. 1 Supportive secondary endpoints showed improvements in liver enzymes, …
Wet Lab vs Dry Lab: Challenges, Benefits and Skills Required
Jan 25, 2023 · Wet Lab. Most web labs require at least a degree in chemistry or biology.However, there are some entry-level roles that require only a high school diploma. Soft skills, such as proper handling techniques, are vital in order to work in a wet lab.
Novo Makes Case to FDA That Semaglutide Is Too Complex for
Oct 23, 2024 · Novo Nordisk is asking the FDA to stop compounding pharmacies from making altered versions of its blockbuster obesity treatment semaglutide, citing the “demonstrable difficulty” of safely producing the drug.. In filings, which the agency posted on its website on Tuesday, Novo nominated semaglutide for inclusion in the FDA’s Demonstrable Difficulties for …